Thurein is the Chief Business Officer of Qrativ, Inc., the biotechnology joint venture formed between nference and the Mayo Clinic. Prior to joining Qrativ, Thurein was VP, Head of Business Development and Corporate Strategy at Novelion Therapeutics, a public biotechnology company focused on the commercialization and development of therapies for rare diseases, including Homozygous Familial Hypercholesterolemia, Generalized Lipodystrophy, and retinal dystrophies such as Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA). During his tenure, he led the strategic merger activities between Aegerion Pharmaceuticals and QLT, Inc. to form Novelion Therapeutics, and also helped to formulate and elucidate Novelion’s future development strategy in targeted metabolic diseases.
Before Novelion, Thurein served for nearly a decade at Pfizer Inc. in roles encompassing Business Development and Disease Area Strategy, particularly in Ophthalmology and Rare Diseases. In addition, Thurein worked in roles across Corporate Development, Product Management, as well as Corporate Strategy at NPS Pharmaceuticals, Inc.
Thurein holds an MBA in Strategy and Health Science Management from the University of Rochester, an MS in Physiology from the University of California at Davis, and a BAS in Neurobiology, Physiology, and Behavior and in Psychology from the University of California at Davis.